Antidepressant Use and Risk of Myocardial Infarction: A Longitudinal Investigation of Sex-Specific Associations in the HUNT Study.
Journal
Psychosomatic medicine
ISSN: 1534-7796
Titre abrégé: Psychosom Med
Pays: United States
ID NLM: 0376505
Informations de publication
Date de publication:
01 01 2023
01 01 2023
Historique:
pubmed:
7
10
2022
medline:
17
12
2022
entrez:
6
10
2022
Statut:
ppublish
Résumé
Antidepressants are thought to affect the risk of cardiovascular disease, although the nature of the association is unclear. Men and women have unique cardiovascular risk factors, and sex differences in depression as well as the efficacy of antidepressants are important to consider. We examined whether antidepressant use was associated with risk of having a myocardial infarction (MI) and whether this association was sex-specific. Data from The Trøndelag Health Study were used, gathered from a population in Norway ( N = 31,765), collected from 1995 to 2008. These data were combined with the Norwegian Cause of Death Registry and the Norwegian Prescription Database. We performed logistic regression models to examine the association of antidepressant use on risk of having a fatal or nonfatal MI, adjusting for depression, anxiety, diabetes, systolic blood pressure, cholesterol, waist-hip ratio, smoking, age, and sex. Results are presented as odds ratios (ORs) and 95% confidence intervals in parentheses. The results indicated that antidepressant use was associated with a reduced risk of having MI at a later date (OR = 0.49 [0.38-0.64]). Although this association was somewhat stronger for women (OR = 0.46 [0.31-0.68]) compared with men (OR = 0.53 [0.37-0.75]), analysis did not identify a sex-specific association of antidepressant use on MI. Follow-up analyses on different subtypes of antidepressants showed that both selective serotonin reuptake inhibitor and tricyclic antidepressant were associated with a reduced risk of MI. In this population study, the use of antidepressants was associated with a reduced risk of MI. This association was stronger for women, although we detected no interaction between sex and antidepressant use in terms of reduced risk of MI. Although limitations apply regarding causality, especially concerning a dose-response relationship, the results suggest that antidepressant use might reduce the risk of MI among both men and women.
Identifiants
pubmed: 36201782
doi: 10.1097/PSY.0000000000001144
pii: 00006842-202301000-00005
doi:
Substances chimiques
Antidepressive Agents
0
Selective Serotonin Reuptake Inhibitors
0
Antidepressive Agents, Tricyclic
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
26-33Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2022 by the American Psychosomatic Society.
Références
Liu Q, He H, Yang J, Feng X, Zhao F, Lyu J. Changes in the global burden of depression from 1990 to 2017: findings from the Global Burden of Disease Study. J Psychiatr Res 2020;126:134–40.
Tamblyn R, Bates DW, Buckeridge DL, Dixon W, Forster AJ, Girard N, et al. Multinational comparison of new antidepressant use in older adults: a cohort study. BMJ Open 2019;9:e027663.
Jakobsen JC, Gluud C, Kirsch I. Should antidepressants be used for major depressive disorder?BMJ Evid Based Med 2020;25:130.
Gan Y, Gong Y, Tong X, Sun H, Cong Y, Dong X, et al. Depression and the risk of coronary heart disease: a meta-analysis of prospective cohort studies. BMC Psychiatry 2014;14:371.
Wu Q, Kling JM. Depression and the risk of myocardial infarction and coronary death. Medicine 2016;95:e2815.
Reis G, dos Santos Moreira-Silva EA, Silva DCM, Thabane L, Milagres AC, Ferreira TS, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health 2022;10:e42–51.
Mortensen JK, Larsson H, Johnsen SP, Andersen G. Post stroke use of selective serotonin reuptake inhibitors and clinical outcome among patients with ischemic stroke: a nationwide propensity score-matched follow-up study. Stroke 2013;44:420–6.
Hansen RA, Khodneva Y, Glasser SP, Qian J, Redmond N, Safford MM. Antidepressant medication use and its association with cardiovascular disease and all-cause mortality in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. Ann Pharmacother 2016;50:253–61.
de Groot M, Marrero D, Mele L, Doyle T, Schwartz F, Mather KJ, et al. Depressive symptoms, antidepressant medication use, and inflammatory markers in the diabetes prevention program. Psychosom Med 2018;80:167–73.
Jang HY, Kim JH, Song YK, Shin JY, Lee HY, Ahn YM, et al. Antidepressant use and the risk of major adverse cardiovascular events in patients without known cardiovascular disease: a retrospective cohort study. Front Pharmacol 2020;11.
Kostev K, Rex J, Eith T, Heilmaier C. Which adverse effects influence the dropout rate in selective serotonin reuptake inhibitor (SSRI) treatment? Results for 50,824 patients. Med Sci 2014;12:Doc15.
Ventetuolo CE, Barr RG, Bluemke DA, Jain A, Delaney JAC, Hundley WG, et al. Selective serotonin reuptake inhibitor use is associated with right ventricular structure and function: the MESA-Right Ventricle Study. PLoS One 2012;7:e30480.
de Abajo FJ, Montero D, Rodriguez LA, Madurga M. Antidepressants and risk of upper gastrointestinal bleeding. Basic Clin Pharmacol Toxicol 2006;98:304–10.
Flöck A, Zobel A, Bauriedel G, Tuleta I, Hammerstingl C, Höfels S, et al. Antiplatelet effects of antidepressant treatment: a randomized comparison between escitalopram and nortriptyline. Thromb Res 2010;126:e83–7.
Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 2011;343:d4551–1.
Siepmann T, Penzlin AI, Kepplinger J, Illigens BM, Weidner K, Reichmann H, et al. Selective serotonin reuptake inhibitors to improve outcome in acute ischemic stroke: possible mechanisms and clinical evidence. Brain Behav 2015;5:e00373.
Almuwaqqat Z, Jokhadar M, Norby FL, Lutsey PL, O’Neal WT, Seyerle A, et al. Association of antidepressant medication type with the incidence of cardiovascular disease in the ARIC study. J Am Heart Assoc 2019;8:e012503.
Pacher P, Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?Curr Pharm Des 2004;10:2463–75.
Undela K, Parthasarathi G, John SS. Impact of antidepressants use on risk of myocardial infarction: a systematic review and meta-analysis. Indian J Pharmacol 2015;47:256–62.
Nezafati MH, Eshraghi A, Vojdanparast M, Abtahi S, Nezafati P. Selective serotonin reuptake inhibitors and cardiovascular events: a systematic review. J Res Med Sci 2016;21:66.
Stewart JC, Polanka BM, So-Armah KA, White JR, Gupta SK, Kundu S, et al. Associations of total, cognitive/affective, and somatic depressive symptoms and antidepressant use with cardiovascular disease–relevant biomarkers in HIV: Veterans Aging Cohort Study. Psychosom Med 2020;82:461–70.
Rieckmann N, Kronish IM, Shapiro PA, Whang W, Davidson KW. Serotonin reuptake inhibitor use, depression, and long-term outcomes after an acute coronary syndrome: a prospective cohort study. JAMA Intern Med 2013;173:1150–1.
Maslej MM, Bolker BM, Russell MJ, Eaton K, Durisko Z, Hollon SD, et al. The mortality and myocardial effects of antidepressants are moderated by preexisting cardiovascular disease: a meta-analysis. Psychother Psychosom 2017;86:268–82.
Lavoie KL, Paine NJ, Pelletier R, Arsenault A, Diodati JG, Campbell TS, et al. Relationship between antidepressant therapy and risk for cardiovascular events in patients with and without cardiovascular disease. Health Psychol 2018;37:989–99.
Hazuda HP, Gaussoin SA, Wing RR, Yanovski SZ, Johnson KC, Coday M, et al. Long-term association of depression symptoms and antidepressant medication use with incident cardiovascular events in the look AHEAD (Action for Health in Diabetes) clinical trial of weight loss in type 2 diabetes. Diabetes Care 2019;42:910–8.
Albrektsen G, Heuch I, Løchen M-L, Thelle DS, Wilsgaard T, Njølstad I, et al. Lifelong gender gap in risk of incident myocardial infarction. JAMA Intern Med 2016;176:1673–9.
Appelman Y, van Rijn BB, ten Haaf ME, Boersma E, Peters SAE. Sex differences in cardiovascular risk factors and disease prevention. Atherosclerosis 2015;241:211–8.
Barth C, Villringer A, Sacher J. Sex hormones affect neurotransmitters and shape the adult female brain during hormonal transition periods. Front Neurosci 2015;9:37.
LeGates TA, Kvarta MD, Thompson SM. Sex differences in antidepressant efficacy. Neuropsychopharmacology 2019;44:140–54.
Albrektsen G, Heuch I, Løchen M-L, Thelle DS, Wilsgaard T, Njølstad I, et al. Risk of incident myocardial infarction by gender: interactions with serum lipids, blood pressure and smoking. The Tromsø Study 1979–2012. Atherosclerosis 2017;261:52–9.
Cho L, Davis M, Elgendy I, Epps K, Lindley KJ, Mehta PK, et al. Summary of updated recommendations for primary prevention of cardiovascular disease in women: JACC state-of-the-art review. J Am Coll Cardiol 2020;75:2602–18.
Zhao M, Woodward M, Vaartjes I, Millett ERC, Klipstein-Grobusch K, et al. Sex differences in cardiovascular medication prescription in primary care: a systematic review and meta-analysis. J Am Heart Assoc 2020;9:e014742.
Hamano T, Li X, Lönn SL, Nabika T, Shiwaku K, Sundquist J, et al. Depression, stroke and gender: evidence of a stronger association in men. J Neurol Neurosurg Psychiatry 2015;86:319–23.
Langvik E, Nordahl HM. Anhedonic depression, history of depression, and anxiety as gender-specific risk factors of myocardial infarction in healthy men and women: the HUNT study. Health Psychol Open 2014;1:205510291455765.
Franconi F, Brunelleschi S, Steardo L, Cuomo V. Gender differences in drug responses. Pharmacol Res 2007;55:81–95.
Bigos KL, Pollock BG, Stankevich BA, Bies RR. Sex differences in the pharmacokinetics and pharmacodynamics of antidepressants: an updated review. Gend Med 2009;6:522–43.
Regitz-Zagrosek V, Oertelt-Prigione S, Prescott E, Franconi F, Gerdts E, Foryst-Ludwig A, et alEUGenMed Cardiovascular Clinical Study Group. Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes. Eur Heart J 2016;37:24–34.
Sramek JJ, Murphy MF, Cutler NR. Sex differences in the psychopharmacological treatment of depression. Dialogues Clin Neurosci 2016;18:447–57.
Cugusi L, Mercuro G. A systematic overview to quantify the gender imbalance in cardiovascular rehabilitation trials. Eur J Prev Cardiol 2019;26:776–81.
Holmen J, Midthjell K, Krüger Ø, Langhammer A, Holmen TL, Bratberg GH, et al. The Nord-Trøndelag Health Study 1995–97 (HUNT 2): objectives, contents, methods and participation. Norsk Epidemiol 2003;13:19–32.
Langhammer A, Krokstad S, Romundstad P, Heggland J, Holmen J. The HUNT study: participation is associated with survival and depends on socioeconomic status, diseases and symptoms. BMC Med Res Methodol 2012;12:143.
Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983;67:361–70.
Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 2002;52:69–77.
Djukanovic I, Carlsson J, Årestedt K. Is the Hospital Anxiety and Depression Scale (HADS) a valid measure in a general population 65–80 years old? A psychometric evaluation study. Health Qual Life Outcomes 2017;15:193.
Midthjell K, Holmen J, Bjørndal A, Lund-Larsen G. Is questionnaire information valid in the study of a chronic disease such as diabetes? The Nord-Trøndelag diabetes study. J Epidemiol Community Health 1992;46:537–42.
Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur J Prev Cardiol 2022;29:5–115.
Thombs BD, Bass EB, Ford DE, Stewart KJ, Tsilidis KK, et al. Prevalence of depression in survivors of acute myocardial infarction. J Gen Intern Med 2006;21:30–8.
Cohen J. A power primer. Psychol Bull 1992;112:155–9.
Lewer D, O’Reilly C, Mojtabai R, Evans-Lacko S. Antidepressant use in 27 European countries: associations with sociodemographic, cultural and economic factors. Br J Psychiatry 2015;207:221–6.
Moore TJ, Mattison DR. Adult utilization of psychiatric drugs and differences by sex, age, and race. JAMA Intern Med 2017;177:274–5.
Norwegian Institute of Public Health. Statistics from the Norwegian Prescription Database. 2020. Available at: https://www.norpd.no/ . Accessed June 22, 2021.
Seldenrijk A, Vogelzangs N, Batelaan NM, Wieman I, van Schaik DJ, Penninx BJ. Depression, anxiety and 6-year risk of cardiovascular disease. J Psychosom Res 2015;78:123–9.
Kim JH, Song YK, Jang HY, Shin JY, Lee HY, Ahn YM, et al. Major adverse cardiovascular events in antidepressant users within patients with ischemic heart diseases: a nationwide cohort study. J Clin Psychopharmacol 2020;40:475–81.
Coupland C, Hill T, Morriss R, Moore M, Arthur A, Hippisley-Cox J. Antidepressant use and risk of cardiovascular outcomes in people aged 20 to 64: cohort study using primary care database. BMJ 2016;352:i1350.
Alqdwah-Fattouh R, Rodríguez-Martín S, de Abajo FJ, González-Bermejo D, Gil M, García-Lledó A, et al. Differential effects of antidepressant subgroups on risk of acute myocardial infarction: a nested case-control study. Br J Clin Pharmacol 2020;86:2040–50.
Gustad LT, Laugsand LE, Janszky I, Dalen H, Bjerkeset O. Symptoms of anxiety and depression and risk of acute myocardial infarction: the HUNT 2 study. Eur Heart J 2014;35:1394–403.
Langvik E, Hjemdal O. Symptoms of depression and anxiety before and after myocardial infarction: the HUNT 2 and HUNT 3 study. Psychol Health Med 2015;20:560–9.
Nicholson A, Kuper H, Hemingway H. Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. Eur Heart J 2006;27:2763–74.